Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 238Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Recurrence 35Burkitt Lymphoma 23Neoplasms 20Neoplasms, Plasma Cell 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Immunoglobulin Light-chain Amyloidosis 13Leukemia 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Lymphoma, B-Cell 6Smoldering Multiple Myeloma 5Nausea 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasm, Residual 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Amyloidosis 4

Interventions

Methods 2pomalidomide 1fasudil 1XENP 1595 1UE2343 1Transurethral Resection of Bladder 1Telemedicine 1Surgical Procedures, Operative 1Standard of Care 1Hormones 1Exercise 1Ethanol 1Electroencephalography 1Drug Delivery Systems 1Dexamethasone 1Control Groups 1Amputation, Surgical 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Alzheimer Disease × Dexamethasone × 1 year × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡